Table 1.

Clinical characteristics of patients in the validation datasets

SPORE New dataGSE13213, Tomida (2009)GSE11969, Matsuyama (2011)GSE8894, Lee (2008)GSE3141, Bild (2006)GSE4573, Raponi (2006)GSE14814, Zhu (2010)
Total patientsn = 176n = 117n = 149n = 138n = 111n = 129n = 90
Gender
 Female83 (47.2%)57 (48.7%)48 (32.2%)34 (24.6%)47 (36.4%)23 (25.6%)
 Male93 (52.8%)60 (51.3%)101 (67.8%)104 (75.4%)82 (63.6%)67 (74.4%)
Stage
 I112 (63.6%)79 (67.5%)78 (52.3%)62 (55.9%)73 (56.6%)45 (50.0%)
 II32 (18.2%)13 (11.1%)26 (17.4%)33 (25.6%)45 (50.0%)
 III30 (17.0%)25 (21.4%)45 (30.2%)23 (17.8%)
 IV1 (0.6%)
 Unknown1 (0.6%)138 (100%)49 (44.1%)
Histology
 ADCs133 (75.6%)117 (100%)90 (60.4%)62 (44.9%)58 (52.3%)28 (31.1%)
 SCCs43 (24.4%)35 (23.5%)76 (55.1%)53 (47.7%)129 (100%)52 (57.8%)
 Others24 (16.1%)10 (11.1%)
Median follow-up (months)47.4687841.831.134.264.8
PlatformIllumina Human-WG6 V3Agilent 44KAgilent 21.6K custom arrayAffy U133 Plus_2Affy. U133 Plus_2Affy. U133AAffy. U133A